ENvue Medical (FEED) sees 21.5% ownership stake reported by Bank of America

Rhea-AI Filing Summary

Bank of America Corporation filed a Schedule 13G reporting beneficial ownership of 234,235 shares of ENvue Medical common stock, representing 21.5% of the outstanding class.

The filing shows Bank of America, through BofA Securities, Inc. and Bank of America N.A., has shared voting and dispositive power over these shares and certifies the position is held in the ordinary course of business without the purpose of influencing control. The disclosure notes that the ownership percentage is based on 1,088,192 outstanding shares from a recent ENvue prospectus, which also describes a potential resale of up to 7,962,279 additional shares that could significantly increase outstanding shares and dilute existing holders.

Insights

Equity ownership analyst

Bank of America discloses a passive 21.5% stake in ENvue Medical common stock.

Bank of America Corporation reports beneficial ownership of 234,235 ENvue Medical shares, equal to 21.5% of the outstanding common stock. The stake is held with shared voting and dispositive power through subsidiaries BofA Securities, Inc. and Bank of America N.A.

The certification states the position is held in the ordinary course of business and not for changing or influencing control, which is consistent with a passive institutional holding under Schedule 13G. This characterizes the exposure as a financial investment or trading position rather than a strategic control move.

The ownership percentage relies on 1,088,192 shares outstanding reported in a December 2025 prospectus that also covers potential resale of up to 7,962,279 shares. The disclosure notes that issuing additional shares under that prospectus could materially increase the share count and cause substantial dilution to existing stockholders, so future changes in outstanding shares may alter this reported percentage.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 04:54 PM Learn about SEC filing dates

FAQ

What does Bank of America’s Schedule 13G reveal about ENvue Medical (FEED)?

Bank of America Corporation reports beneficial ownership of 234,235 ENvue Medical common shares, representing 21.5% of the class. The shares are held with shared voting and dispositive power through subsidiaries BofA Securities, Inc. and Bank of America N.A. under a passive Schedule 13G filing.

How many ENvue Medical (FEED) shares does Bank of America beneficially own?

Bank of America beneficially owns 234,235 shares of ENvue Medical common stock. This stake reflects shared voting and dispositive power, with no sole authority, and corresponds to 21.5% of the outstanding common shares based on an issuer share count from a recent ENvue prospectus.

What percentage of ENvue Medical’s common stock does Bank of America hold?

Bank of America reports beneficial ownership of 21.5% of ENvue Medical’s common stock. This percentage is calculated using 1,088,192 outstanding shares disclosed in a December 2025 ENvue prospectus, making Bank of America a significant institutional holder of the company’s equity securities.

Is Bank of America seeking control of ENvue Medical (FEED) with this stake?

The filing states the securities were acquired and are held in the ordinary course of business, not to change or influence control. Bank of America certifies the position is not connected with any control-seeking transaction, aligning the disclosure with passive ownership under Schedule 13G rules.

How could ENvue Medical’s registered resale shares affect existing stockholders?

ENvue’s referenced prospectus covers potential resale of up to 7,962,279 common shares. The disclosure notes that issuing additional shares under this prospectus could materially increase outstanding common shares and result in substantial dilution to existing stockholders compared to the 1,088,192 shares currently outstanding.

Which Bank of America entities are associated with the ENvue Medical position?

The statement is filed by Bank of America Corporation on behalf of itself and wholly owned subsidiaries BofA Securities, Inc. and Bank of America N.A. BofA Securities is a registered broker-dealer, while Bank of America N.A. is a bank as defined under the Securities Exchange Act.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ENvue Medical, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

63008J884

(CUSIP Number)

01/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 63008J884

1

Names of Reporting Persons

BANK OF AMERICA CORP /DE/

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 234,235.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 234,235.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

234,235.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

21.5 %

12

Type of Reporting Person (See Instructions)

HC

Comment for Type of Reporting Person: The beneficial ownership calculation relies on the 1,088,192 outstanding shares disclosed in the Form 424B3 - Prospectus by the issuer on December 18, 2025, which reports share totals as of December 5, 2025. The prospectus pertains to the resale, from time to time, by selling stockholders of up to 7,962,279 shares of common stock. While not yet finalized, the issuance of additional shares could materially increase the number of outstanding common shares and result in substantial dilution to existing stockholders.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ENvue Medical, Inc.
(b)	Address of issuer's principal executive offices: 969 PRUITT AVE,, TYLER, TEXAS, 77569.
Item 2.
(a)	Name of person filing: BANK OF AMERICA CORP /DE/
(b)	Address or principal business office or, if none, residence: 100 N TRYON ST CHARLOTTE, NC 28255
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 63008J884
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 234,235.00
(b)	Percent of class: 21.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0.00
	(ii) Shared power to vote or to direct the vote: 234,235.00
	(iii) Sole power to dispose or to direct the disposition of: 0.00
	(iv) Shared power to dispose or to direct the disposition of: 234,235.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); and Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BANK OF AMERICA CORP /DE/

Signature:	/s/ Andres Ortiz
Name/Title:	Authorized Signatory
Date:	02/06/2026